• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Oruka Therapeutics Inc.

    3/12/26 4:25:02 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ORKA alert in real time by email
    S-8 1 ea0280319-s8_oruka.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on March 12, 2026

    Registration No. 333-                 

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM S-8

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

     

    Oruka Therapeutics, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   36-3855489
    (State or Other Jurisdiction of
    Incorporation or Organization)
      (I.R.S. Employer
    Identification Number)

     

    Oruka Therapeutics, Inc.
    855 Oak Grove Avenue, Suite 100
    Menlo Park, California 94025

    (Address of Principal Executive Offices, Zip Code)

     

    Oruka Therapeutics, Inc. 2024 Stock Incentive Plan

    (Full title of the plan)

     

    Paul Quinlan
    General Counsel and Corporate Secretary
    Oruka Therapeutics, Inc.
    855 Oak Grove Avenue, Suite 100
    Menlo Park, California 94025
    (650) 606-7910

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    With a copy to:

     

    Alan F. Denenberg
    Elizabeth W. LeBow
    Davis Polk & Wardwell LLP
    900 Middlefield Road Redwood City, California 94063
    (650) 752-2000

     

     

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed by Oruka Therapeutics, Inc., a Delaware corporation (the “Registrant”), pursuant to General Instruction E to Form S-8, under the Securities Act of 1933, as amended (the “Securities Act”), in order to register an additional 3,354,715 shares of its common stock, par value $0.001 per share (the “Common Stock”), issuable under the Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (the “SIP”), pursuant to the provisions of the SIP providing for an automatic increase in the number of shares reserved for issuance under such plan.

     

    The information contained in the Registrant’s registration statements on Form S-8 previously filed with the Securities and Exchange Commission (the “Commission”) on November 14, 2024 (File No. 333-283243) and March 6, 2025 (File No. 333-285601), together with all exhibits filed therewith or incorporated therein by reference, are hereby incorporated by reference pursuant to General Instruction E to Form S-8, and the shares of Common Stock registered hereunder are in addition to the shares of Common Stock registered on such registration statement with respect to the SIP. In accordance with the instructional note to Part I of the Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement.

     

     

     

    PART II
    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents are incorporated herein by reference:

     

    (a) The Registrant’s Annual Report on Form 10-K for the year ended December 31, 2025 (the “Annual Report”), filed with the Commission on March 12, 2026; and

     

    (b) The description of the Registrant’s capital stock, which is contained in Exhibit 4.1 to the Registrant’s Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Commission on March 6, 2025.

     

    All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents; except as to any portion of any future annual or quarterly report to stockholders or document or current report furnished under current Items 2.02 or 7.01 of Form 8-K that is not deemed filed under such provisions. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    Item 8. Exhibits.

     

    Exhibit No.     Exhibit Description  
    4.1   Second Amended and Restated Certificate of Incorporation of Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 3.5 of the Registrant’s Current Report on Form 8-K, filed with the Commission on September 5, 2024).
    4.2   Amended and Restated Bylaws of Oruka Therapeutics, Inc. (incorporated by reference to Exhibit 3.6 of the Registrant’s Current Report on Form 8-K, filed with the Commission on September 5, 2024).
    5.1*   Opinion of Davis Polk & Wardwell LLP.
    23.1*   Consent of Independent Registered Public Accounting Firm.
    23.2*   Consent of Davis Polk & Wardwell LLP (included in Exhibit 5.1).
    24.1*   Power of Attorney (included on the signature page to this Registration Statement).
    99.1   Oruka Therapeutics, Inc. 2024 Stock Incentive Plan (incorporated by reference to Exhibit 10.10 of the Registrant’s Current Report on Form 8-K, filed with the Commission on September 5, 2024).
    107.1*   Filing Fee Table.

     

     

    *Filed herewith.

     

    II-1

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Menlo Park California, on the 12th day of March, 2026.

     

      ORUKA THERAPEUTICS, INC.
       
      By: /s/ Lawrence Klein
        Name: Lawrence Klein
        Title: Chief Executive Officer

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Lawrence Klein, Arjun Agarwal, and Paul Quinlan and each of them (with full power to each of them to act alone), the individual’s true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorneys-in-fact and agents, or any of them, or their substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
             
    /s/ Lawrence Klein   Chief Executive Officer and Director   March 12, 2026
    Lawrence Klein   (principal executive officer)    
             
    /s/ Arjun Agarwal   Senior Vice President, Finance and Treasurer   March 12, 2026
    Arjun Agarwal   (principal financial and accounting officer)    
             
    /s/ Samarth Kulkarni   Chairman of the Board   March 12, 2026
    Samarth Kulkarni        
             
    /s/ Kristine Ball   Director   March 12, 2026
    Kristine Ball        
             
    /s/ Carl Dambkowski   Director   March 12, 2026
    Carl Dambkowski        
             
    /s/ Peter Harwin   Director   March 12, 2026
    Peter Harwin        
             
    /s/ Christopher Martin   Director   March 12, 2026
    Christopher Martin        

     

    II-2

     

    Get the next $ORKA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ORKA

    DatePrice TargetRatingAnalyst
    12/18/2025$75.00Overweight
    Piper Sandler
    11/13/2025$45.00Buy
    Jefferies
    10/27/2025$60.00Buy
    Guggenheim
    10/13/2025$48.00Overweight
    Barclays
    5/22/2025$44.00Buy
    BTIG Research
    2/4/2025$20.00Outperform
    Wolfe Research
    10/11/2024$49.00Buy
    Stifel
    10/7/2024$45.00Buy
    H.C. Wainwright
    More analyst ratings

    $ORKA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Venrock Healthcare Capital Partners Iii, L.P. bought $1,407,368 worth of shares (122,882 units at $11.45) (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    2/27/25 6:42:49 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Klein Lawrence Otto sold $71,408 worth of shares (1,729 units at $41.30), decreasing direct ownership by 0.19% to 927,309 units (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    3/17/26 4:10:21 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Senior Vice President, Finance Agarwal Arjun sold $16,313 worth of shares (395 units at $41.30), decreasing direct ownership by 2% to 18,863 units (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    3/17/26 4:09:21 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Chief Operating Officer Sandler Laura Lee sold $24,780 worth of shares (600 units at $41.30), decreasing direct ownership by 0.25% to 236,984 units (SEC Form 4)

    4 - Oruka Therapeutics, Inc. (0000907654) (Issuer)

    3/17/26 4:08:09 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Oruka Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

    ORKA-001 EVERLAST-A 16-week data now expected in 2Q 2026 following rapid enrollment, with longer-term follow-up data expected in 2H 2026 ORCA-SURGE Phase 2 trial of ORKA-002 in psoriasis initiated with data expected 2027 $479.6 million in cash, cash equivalents and marketable securities MENLO PARK, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today reported fourth quarter and full year 2025 financial results and provided a corporate update. "We are very pleased with

    3/12/26 4:05:20 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Oruka Therapeutics to Participate in Multiple Upcoming Conferences

    MENLO PARK, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis, today announced its participation and presentation at multiple upcoming conferences: Guggenheim Emerging Outlook: Biotech Summit 2026Date: Thursday, February 12th, 2026Presentation Time: 10:30AM ET TD Cowen 46th Annual Health Care ConferenceDate: Tuesday, March 3rd, 2026Presentation Time: 1:10PM ET UBS Biotech Summit MiamiDate: Monday March 9th, 2026 Jefferies Biotech on the Beach SummitDate: March 10th, 2026 Leerink

    2/9/26 7:00:00 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001

    ORKA-002 interim Phase 1 data demonstrates a half-life of 75-80 days supporting potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of ORKA-001 in December 2025 with data expected in 2027 MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announc

    1/12/26 7:00:00 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Piper Sandler initiated coverage on Oruka Therapeutics with a new price target

    Piper Sandler initiated coverage of Oruka Therapeutics with a rating of Overweight and set a new price target of $75.00

    12/18/25 9:11:03 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Jefferies initiated coverage on Oruka Therapeutics with a new price target

    Jefferies initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $45.00

    11/13/25 9:15:29 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Guggenheim initiated coverage on Oruka Therapeutics with a new price target

    Guggenheim initiated coverage of Oruka Therapeutics with a rating of Buy and set a new price target of $60.00

    10/27/25 8:48:30 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Oruka Therapeutics Inc.

    SCHEDULE 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    3/27/26 11:04:41 AM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form S-8 filed by Oruka Therapeutics Inc.

    S-8 - Oruka Therapeutics, Inc. (0000907654) (Filer)

    3/12/26 4:25:02 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 10-K filed by Oruka Therapeutics Inc.

    10-K - Oruka Therapeutics, Inc. (0000907654) (Filer)

    3/12/26 4:03:28 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Leadership Updates

    Live Leadership Updates

    View All

    Oruka Therapeutics Announces New Board Member and Board Transition

    MENLO PARK, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Oruka Therapeutics, Inc. ("Oruka") (NASDAQ:ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO), today announced the appointment of Chris Martin to its Board of Directors. Additionally, Cameron Turtle, DPhil, resigned from the Board effective December 11, 2025. "As we rapidly advance our co-lead programs through development, I'm pleased to announce this board transition at Oruka," said Lawrence Klein, PhD, Chief Executive Officer of Oruka Therapeutics. "Chris's expertise can bring tremendous value to the compan

    12/11/25 4:01:00 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $ORKA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Oruka Therapeutics Inc.

    SC 13D/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/21/24 6:30:53 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

    SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/14/24 7:38:47 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Oruka Therapeutics Inc.

    SC 13G/A - Oruka Therapeutics, Inc. (0000907654) (Subject)

    11/14/24 5:49:56 PM ET
    $ORKA
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care